WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Resources > Whitepapers > The SiriusDecisions B-to-B Buying Decision Process Framework
July 8, 2019
I'm For Real
Enter your details once to access all our information and resources
Impel Pharmaceuticals is focused on developing and providing transformative therapies for people suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system (CNS)
whitePaper | January 5, 2023
This report follows up on the jointly hosted Pharmaforce and elandas webinar which took place on July, 12, 2016, featuring contributions from participating industry leaders who formed the expert panel, as well as the live contributions of the audience of healthcare sales and marketing professionals.
whitePaper | June 27, 2022
As the world begins its transition into a postpandemic existence, it becomes possible to look back on the past two years and begin to quantify the effects that COVID-19 has brought.
whitePaper | November 11, 2022
Tremendous technological advancements in automated biotechnology and combinatorial chemistry have led to the widespread implementation of high throughput screening (HTS) for drug discovery since the early 1990s.
whitePaper | December 15, 2022
Successful execution of clinical trials requires the orchestration of multiple moving parts, with everything from protocol design and patient visit schedules, to lab kits and biological samples needing to seamlessly line up to ensure on-time, on-budget delivery of high-quality data.
whitePaper | August 8, 2021
If Pharma is to create a new marketing and sales model that is fit for 2020, it will have to begin by analysing its own value chain to identify opportunities for working more closely with healthcare payers and providers. It will, for example, have to collaborate much more closely with payers (be they governments, health insurers, employers or patients) to ensure that it develops medicines which have real social and economic value.
whitePaper | October 7, 2022
The Drug Supply Chain Security Act is one component of the DQSA. This particular act requires the FDA to implement a national track-and-trace system by which manufacturers must affix product identifiers (barcodes) to each package of product that is introduced into the supply chain.
Conference
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE